Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. aurigen

AuriGen SIGNED

Next Generation Left Atrial Appendage Implant to Treat Persistent Atrial Fibrillation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 AuriGen project word cloud

Explore the words cloud of the AuriGen project. It provides you a very rough idea of what is the project "AuriGen" about.

tissue    approximately    arrhythmia    entering    treatment    implants    shot    france    million    mechanically    electrically    af    least    appendage    persistent    cardiac    invasive    isolation    electrical    destroys    launch    ce    fit    works    surgery    therapy    stream    flow    wasted    financially    specialist    time    approval    paf    patients    hours    atrial    heart    redo    contraction    italy    stroke    implant    muscle    germany    too    abnormal    procedure    markets    clots    fibrillation    permanently    caused    72    blood    enter    market    classified    treating    commercial    13    shut    first    expand    isolates    fitting    causing    surgical    doubles    doubled    uk    opening    human    prevent    minimally    complete    billion    healthcare    distributors    occlusion    incapable    health    opportunity    device    services    irregular    tier    5bn    30    risk    pulses    left    rates    international    filter    heartbeat    clinical    amounting    laa   

Project "AuriGen" data sheet

The following table provides information about the project.

Coordinator		 AURIGEN MEDICAL LIMITED 

Organization address
address: 18 CHURCHWELL SQUARE
city: DUBLIN
postcode: DUBLIN 13
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Ireland [IE]
 Project website http://www.aurigenmedical.com
 Total cost 3˙503˙093 €
 EC max contribution 2˙452˙165 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AURIGEN MEDICAL LIMITED IE (DUBLIN) coordinator 2˙452˙165.00

Map

 Project objective

Atrial Fibrillation (AF) is an irregular heartbeat that can lead to blood clots, high risk of stroke and heart failure. AF is caused by abnormal electrical activity in the heart. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF). Surgical treatment for AF is a minimally invasive electrical therapy which destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients.

We have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. EU and US PAF represents a $5bn/yr market opportunity. We will enter the market directly in our target Tier 1 European markets (Germany, France, Italy and UK). We will scale using specialist distributors to expand into further European, US and other international markets.

In this Phase 2 we will complete the technical, pre-clinical and first in human clinical studies required to achieve CE approval in Europe as well as market development work for commercial launch.

 Deliverables

List of deliverables.
Sales Director Appointed Other 2019-11-25 12:36:59
Operations Director Appointed Other 2019-11-25 12:36:58

Take a look to the deliverables list in detail:  detailed list of AuriGen deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURIGEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURIGEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Osto.Me (2020)

Ostomy Market Disruption: First Leak Proof Ostomy Appliance removing the need for Accessories in the Ostomy Market

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More